SARcode Bioscience Report issue

Contributed to NME For profit Phase 3
Founded: Brisbane CA United States (2006)
Status: Acquired by Shire (2013) → now Takeda (2018)

Organization Overview

First Clinical Trial
2009
NCT00936520
First Marketed Drug
2008
lifitegrast (xiidra)
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SARcode Bioscience, Inc.

Active Ingredients

Marketed Drugs (1)

lifitegrast (xiidra) (2008)

Drugs in Phase 3 Trials (1)

lifitegrast (xiidra) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dry Eye Syndromes (Phase 3)

Eye Diseases (Phase 3)

Keratoconjunctivitis (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Macular Edema (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1